<DOC>
	<DOCNO>NCT01402219</DOCNO>
	<brief_summary>The purpose study compare incidence contrast-induced nephropathy ( CIN ) follow administration iopamidol-370 ( Iopamiro-370 ) iodixanol-320 ( Visipaque 320 ) patient chronic kidney disease undergo coronary angiography .</brief_summary>
	<brief_title>Nephrotoxicity Iopamidol Versus Iodixanol High-Risk Patients</brief_title>
	<detailed_description>To compare incidence contrast-induced nephropathy ( CIN ) ( absolute SCr increase 0.5 mg/dL baseline ) follow administration iopamidol-370 ( Iopamiro-370 ) iodixanol-320 ( Visipaque 320 ) patient chronic kidney disease ( serum creatinine level 1.5 mg/dL men 1.3 mg/dL woman preprocedural estimate glomerular ﬁltration rate ( eGFR ) :15-60 mL/min/1.73 m2 ) undergo coronary angiography .</detailed_description>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<criteria>Provides write Informed Consent willing comply protocol requirement Is ≥18 year age Has document predose serum creatinine level ≥1.5 mg/dL men ≥ 1.3 mg/dL woman predose estimate glomerular ﬁltration rate ( eGFR ) &gt; 15 ≤ 60 mL/min/1.73 m2 , calculate via MDRD formula SCr obtain within 72 hour enrollment study ; Is refer cardiac angiography without PCI ; If discretion Investigator receive receive prophylactic medication renal function , medication one permit protocol ( N acetylcysteine , 1200 mg twice daily day day cardiac angiography procedure ) ; Undergoes schedule undergo pre , peri , post procedure hydration permit protocol , i.e . : 154 mEq/L sodium bicarbonate solution , administer intravenously 3 mL/kg/hr 1 hour cardiac angiography , follow infusion 1 mL/kg/hr 6 hour cardiac angiography , 0.9 % normal saline administer intravenously 1 mL/kg/hr 812 hour cardiac angiography , follow infusion 1 mL/kg/hr 24 hour cardiac angiography , patient leave ventricular ejection fraction &lt; 35 % congestive heart failure ( class III accordance classification New York Heart Association ( NYHA ) , rate infusion decrease half ordinary rate . Is pregnant lactate female . Exclude possibility pregnancy : laboratory test onsite institution ( measurement serum urine βHCG ) within 24 hour prior start investigational product administration history ( e.g. , tubal ligation hysterectomy , post menopausal minimum 1 year without menses ) Has history hypersensitivity iodinecontaining compound ; Has unstable renal function ( i.e. , acute worsen renal function , determine Investigator , observe 7 day prior enrollment ) and/or acute renal failure ; Has endstage renal disease ( i.e. , eGFR &lt; 15 mL/min/1.73 m2 ) Has severe congestive heart failure ( class IV accordance classification New York Heart Association ( NYHA ) ; Has uncontrolled diabetes , determine Investigator ; Has receive iodinate contrast agent within 7 day prior administration study agent schedule receive iodinate contrast agent within 72 hour administration study agent ; intake nephrotoxic drug within previous seven day Prior , post cardiac angiography , receive receive prophylactic medication prevent acute kidney injury permit protocol ( e.g. , theophylline , fenoldopam , etc . ) ; Is plan undergo major surgery ( e.g . CABG , valve surgery , etc . ) within 4872 hour contrast administration ; Is plan receive intravenous diuretic mannitol prophylaxis prevent acute renal injury ( Note : chronic administration allow ) ; Is hemodynamically unstable within 48 hour precontrast administration define systolic blood pressure &lt; 90 mmHg require pressor intraaortic balloon support</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>contrast-induced nephropathy</keyword>
	<keyword>contrast medium</keyword>
	<keyword>creatinine clearance</keyword>
	<keyword>coronary angiography</keyword>
	<keyword>chronic kidney disease</keyword>
</DOC>